Using cost-effectiveness analysis to sharpen formulary decision-making: The example of tiotropium at the veterans affairs health care system

Ebere Onukwugha, C. Daniel Mullins, Sylvain DeLisle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To identify a cost-saving subset of criteria for the use of tiotropium at a Veterans Affairs Medical Center based on a cost-effectiveness analysis with ipratropium as the comparator. Methods: Retrospective analysis of electronic medical records for the calendar year 2004 was conducted. The sample was drawn from a population at the Baltimore Veterans Affairs Medical Center that had a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) and had filled prescriptions for ipratropium. The tiotropium sample was based on a modeled cohort of COPD patients who had received tiotropium. The analysis was conducted from the perspective of the Veterans Affairs Health Care System. The outcome was the incremental cost-effectiveness of tiotropium versus ipratropium. Results: The incremental cost-effectiveness ratio (ICER) was $2360 per avoided exacerbation. Tiotropium cost-effectiveness increased with COPD severity and was cost-saving in patients with very severe disease (ICER = $-1818) and in patients with a previous COPD-related hospitalization (ICER = $-4472). The ICER was most sensitive to the relative effectiveness and price of tiotropium. Results identified the levels of treatment effectiveness and price beyond which tiotropium would become cost-saving relative to ipratropium. Conclusions: The results support the existing Veterans Affairs practice of offering tiotropium to patients with COPD-related hospitalizations. Periodic review of the effectiveness data to determine whether tiotropium would be cost-saving in patients with very severe COPD is suggested. Cost-effectiveness analyses that identify practical criteria-for-use should become an integral part of the formulary process.

Original languageEnglish (US)
Pages (from-to)980-988
Number of pages9
JournalValue in Health
Volume11
Issue number5
DOIs
StatePublished - Jan 1 2008

Fingerprint

Veterans Health
Formularies
Cost-Benefit Analysis
Decision Making
Delivery of Health Care
Chronic Obstructive Pulmonary Disease
Ipratropium
Veterans
Costs and Cost Analysis
Hospitalization
Tiotropium Bromide
Baltimore
Cost of Illness
Electronic Health Records
Prescriptions

Keywords

  • Chronic obstructive pulmonary disease
  • Cost-effectiveness
  • Formulary decision-making
  • Tiotropium
  • Veterans population

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Using cost-effectiveness analysis to sharpen formulary decision-making : The example of tiotropium at the veterans affairs health care system. / Onukwugha, Ebere; Mullins, C. Daniel; DeLisle, Sylvain.

In: Value in Health, Vol. 11, No. 5, 01.01.2008, p. 980-988.

Research output: Contribution to journalArticle

@article{8d1d2c86f6b9420a8334ecc2f8447c3d,
title = "Using cost-effectiveness analysis to sharpen formulary decision-making: The example of tiotropium at the veterans affairs health care system",
abstract = "Objective: To identify a cost-saving subset of criteria for the use of tiotropium at a Veterans Affairs Medical Center based on a cost-effectiveness analysis with ipratropium as the comparator. Methods: Retrospective analysis of electronic medical records for the calendar year 2004 was conducted. The sample was drawn from a population at the Baltimore Veterans Affairs Medical Center that had a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) and had filled prescriptions for ipratropium. The tiotropium sample was based on a modeled cohort of COPD patients who had received tiotropium. The analysis was conducted from the perspective of the Veterans Affairs Health Care System. The outcome was the incremental cost-effectiveness of tiotropium versus ipratropium. Results: The incremental cost-effectiveness ratio (ICER) was $2360 per avoided exacerbation. Tiotropium cost-effectiveness increased with COPD severity and was cost-saving in patients with very severe disease (ICER = $-1818) and in patients with a previous COPD-related hospitalization (ICER = $-4472). The ICER was most sensitive to the relative effectiveness and price of tiotropium. Results identified the levels of treatment effectiveness and price beyond which tiotropium would become cost-saving relative to ipratropium. Conclusions: The results support the existing Veterans Affairs practice of offering tiotropium to patients with COPD-related hospitalizations. Periodic review of the effectiveness data to determine whether tiotropium would be cost-saving in patients with very severe COPD is suggested. Cost-effectiveness analyses that identify practical criteria-for-use should become an integral part of the formulary process.",
keywords = "Chronic obstructive pulmonary disease, Cost-effectiveness, Formulary decision-making, Tiotropium, Veterans population",
author = "Ebere Onukwugha and Mullins, {C. Daniel} and Sylvain DeLisle",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1524-4733.2007.00314.x",
language = "English (US)",
volume = "11",
pages = "980--988",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Using cost-effectiveness analysis to sharpen formulary decision-making

T2 - The example of tiotropium at the veterans affairs health care system

AU - Onukwugha, Ebere

AU - Mullins, C. Daniel

AU - DeLisle, Sylvain

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objective: To identify a cost-saving subset of criteria for the use of tiotropium at a Veterans Affairs Medical Center based on a cost-effectiveness analysis with ipratropium as the comparator. Methods: Retrospective analysis of electronic medical records for the calendar year 2004 was conducted. The sample was drawn from a population at the Baltimore Veterans Affairs Medical Center that had a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) and had filled prescriptions for ipratropium. The tiotropium sample was based on a modeled cohort of COPD patients who had received tiotropium. The analysis was conducted from the perspective of the Veterans Affairs Health Care System. The outcome was the incremental cost-effectiveness of tiotropium versus ipratropium. Results: The incremental cost-effectiveness ratio (ICER) was $2360 per avoided exacerbation. Tiotropium cost-effectiveness increased with COPD severity and was cost-saving in patients with very severe disease (ICER = $-1818) and in patients with a previous COPD-related hospitalization (ICER = $-4472). The ICER was most sensitive to the relative effectiveness and price of tiotropium. Results identified the levels of treatment effectiveness and price beyond which tiotropium would become cost-saving relative to ipratropium. Conclusions: The results support the existing Veterans Affairs practice of offering tiotropium to patients with COPD-related hospitalizations. Periodic review of the effectiveness data to determine whether tiotropium would be cost-saving in patients with very severe COPD is suggested. Cost-effectiveness analyses that identify practical criteria-for-use should become an integral part of the formulary process.

AB - Objective: To identify a cost-saving subset of criteria for the use of tiotropium at a Veterans Affairs Medical Center based on a cost-effectiveness analysis with ipratropium as the comparator. Methods: Retrospective analysis of electronic medical records for the calendar year 2004 was conducted. The sample was drawn from a population at the Baltimore Veterans Affairs Medical Center that had a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) and had filled prescriptions for ipratropium. The tiotropium sample was based on a modeled cohort of COPD patients who had received tiotropium. The analysis was conducted from the perspective of the Veterans Affairs Health Care System. The outcome was the incremental cost-effectiveness of tiotropium versus ipratropium. Results: The incremental cost-effectiveness ratio (ICER) was $2360 per avoided exacerbation. Tiotropium cost-effectiveness increased with COPD severity and was cost-saving in patients with very severe disease (ICER = $-1818) and in patients with a previous COPD-related hospitalization (ICER = $-4472). The ICER was most sensitive to the relative effectiveness and price of tiotropium. Results identified the levels of treatment effectiveness and price beyond which tiotropium would become cost-saving relative to ipratropium. Conclusions: The results support the existing Veterans Affairs practice of offering tiotropium to patients with COPD-related hospitalizations. Periodic review of the effectiveness data to determine whether tiotropium would be cost-saving in patients with very severe COPD is suggested. Cost-effectiveness analyses that identify practical criteria-for-use should become an integral part of the formulary process.

KW - Chronic obstructive pulmonary disease

KW - Cost-effectiveness

KW - Formulary decision-making

KW - Tiotropium

KW - Veterans population

UR - http://www.scopus.com/inward/record.url?scp=52649134595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649134595&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4733.2007.00314.x

DO - 10.1111/j.1524-4733.2007.00314.x

M3 - Article

C2 - 18194405

AN - SCOPUS:52649134595

VL - 11

SP - 980

EP - 988

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 5

ER -